Get the Stockscreener App
1.88
4.57%
-0.09
After Hours:
1.88
Rein Therapeutics Inc stock is traded at $1.88, with a volume of 83,367.
It is down -4.57% in the last 24 hours and down -4.08% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.97
Open:
$1.8
24h Volume:
83,367
Relative Volume:
2.39
Market Cap:
$44.31M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.00%
1M Performance:
-4.08%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.69
$1.93
1-Week Range:
$1.69
$2.02
52-Week Range:
$1.35
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.88 | 44.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
Rein Therapeutics Paused Its Phase 2 Renew Trial Of Lti-03 In The U.S. - marketscreener.com
Rein Therapeutics Pauses U.S. Enrollment for RENEW Trial - TipRanks
Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold - TradingView
New National Poll Finds Overwhelming Majorities of Voters Want "America First" Reforms of Big Pharma’s Business Practices, Want to Limit Direct-to-Consumer Pharmaceutical Advertising, & Support President Trump’s Executive Order on Drug Pricing - Yahoo Finance
KC GLOBAL MEDIA AND REIN ENTERTAINMENT JOIN FORCES FOR A RIVETING REALITY-DRIVEN DRUG WAR SERIES - Yahoo Finance
In Spain, short-term rentals surge despite bid to rein in overtourism - Yahoo
President Trump Should Rein in Biden Era Actions Targeting U.S. Businesses - Yahoo
Rein Therapeutics doses first subject in Phase II trial to treat IPF - Yahoo Finance
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf - marketscreener.com
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV S - GuruFocus
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV Stock News - GuruFocus
Breakthrough IPF Drug Enters Phase 2 Trial: Rein's Novel Treatment Could Transform Pulmonary Fibrosis Care - Stock Titan
Knee Pain Relief Through The Ear? New Study Says It's Possible - WFMZ.com
U.S. Had 1.5 Million Excess Deaths Following Pandemic - WFMZ.com
Exercise Improves Odds Against Cancer - WFMZ.com
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Recruitment underway for Phase 2 trial of IPF inhalation therapy - Pulmonary Fibrosis News
Prices for new US drugs doubled in 4 years as focus on rare disease grows - Reuters
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - Nasdaq
Rein Therapeutics Reports Q1 2025 Financial Results - TipRanks
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GuruFocus
Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment - Yahoo Finance
Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
Rein Therapeutics (RNTX) Begins Phase 2 Trial for IPF Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Rein Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment - Yahoo Finance
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Citizen Tribune
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - The Victoria Advocate
Breakthrough Lung Regeneration Study: Rein Therapeutics to Present New IPF Treatment Data at ATS 2025 - Stock Titan
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - The Malaysian Reserve
Rein Therapeutics (RNTX) Secures Two Key Patents for Innovative Lung Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Antibiotics Might Increase Risk of Childhood Asthma, Allergies - WFMZ.com
Muscle Quality Could Be Key To Successful Hip Replacement - WFMZ.com
Early Menopause Might Mean Greater Age-Related Brain Decline - WFMZ.com
Microplastics Could Be Contributing To Clogged Arteries - WFMZ.com
Psilocybin Use Dramatically Increasing In U.S. - WFMZ.com
Tesla Board Gets an Earful From State Treasurers Over Musk’s Focus - Yahoo Finance
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial - Frontiers
Rein Therapeutics Announces a Publication in Biomedicines on the - GuruFocus
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - MarketScreener
Cancer-fighting implant shows promise in treating tumors - WFMZ.com
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 17 '24 |
Sale |
3.25 |
4,707 |
15,298 |
1,746,549 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):